Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct 20;6(32):32545-60.
doi: 10.18632/oncotarget.5324.

MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis

Liangyou Gu  1 , Hongzhao Li  1 , Luyao Chen  1 , Xin Ma  1 , Yu Gao  1 , Xintao Li  1 , Yu Zhang  1 , Yang Fan  1 , Xu Zhang  1
Affiliations
Meta-Analysis

MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis

Liangyou Gu et al. Oncotarget. .

Abstract

This is a systematic review of studies investigating the prognostic value of different microRNAs (miRs) in renal cell carcinoma (RCC). Twenty-seven relevant studies were identified, with a total of 2578 subjects. We found that elevated expression of miR-21, miR-1260b, miR-210, miR-100, miR-125b, miR-221, miR-630, and miR-497 was associated with a poor prognosis in RCC patients. Conversely, decreased expression of miR-106b, miR-99a, miR-1826, miR-215, miR-217, miR-187, miR-129-3p, miR-23b, miR-27b, and miR-126 was associated with a worse prognosis. We performed meta-analyses on studies to address the prognostic value of miR-21, miR-126, miR-210, and miR-221. This revealed that elevated miR-21 expression was associated with shorter overall survival (OS; hazard ratio [HR], 2.29; 95% confidence interval [CI], 1.28-4.08), cancer specific survival (CSS; HR, 4.16; 95% CI, 2.49-6.95), and disease free survival (DFS; HR, 2.15; 95% CI, 1.16-3.98). The decreased expression of miR-126 was associated with shorter CSS (HR, 0.35; 95% CI, 0.15-0.85), OS (HR, 0.45; 95% CI, 0.30-0.69), and DFS (HR 0.30; 95% CI, 0.18-0.50). Our comprehensive systematic review reveals that miRs, especially miR-21 and miR-126, could be promising prognostic markers and useful therapeutic targets in RCC.

Keywords: meta-analysis; microRNA; prognosis biomarker; renal cell carcinoma; survival.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1. Flowchart of selecting studies for inclusion
Figure 2
Figure 2. Hazard ratios (HR) of miRs
The point estimate is bounded by a 95% confidence interval (CI), and the perpendicular line represents no increased risk for the outcome. OS = overall survival; CSS = cancer specific survival; DFS = disease free survival; RFS = recurrence free survival.
Figure 3
Figure 3. Forest plots of studies evaluating hazard ratios of aberrant miR-21 and mir-126 expression
A. miR-21, OS, CSS, DFS; B. miR-126, CSS, OS, DFS. OS = overall survival; CSS = cancer specific survival; DFS = disease free survival; HR = hazard ratio.
Figure 4
Figure 4. Forest plots of studies evaluating hazard ratios of aberrant miR-210 and mir-221 expression
A. miR-210, OS, CSS, DFS, RFS; B. miR-221, CSS, OS. OS = overall survival; CSS = cancer specific survival; DFS = disease free survival; RFS = recurrence free survival; HR = hazard ratio.
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29. - PubMed
    1. Murai M, Oya M. Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004;14:229–233. - PubMed
    1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490. - PubMed
    1. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59:18–23. - PubMed
    1. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol. 2009;56:636–643. - PubMed

Publication types

MeSH terms